KRAS and adenocarcinoma: After four courses of nivolumab, the second patient (a KRAS-G12D-mutated adenocarcinoma) also reported a clinical benefit, contrasting with a worrying condensation of lung metastases and a global increase in tumor burden on the first CT-scan (Figure 2).